Clinical Trials Browser

INDUSTRY × Neoplasms × niraparib × Clear all

NCT06077877 2026-02-02

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT04544995 2026-01-21

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

Phase 1 Terminated

47 enrolled 43 charts

Neoplasms, Neuroblastoma, Osteosarcoma

NCT03307785 2025-11-25

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Phase 1 Completed

60 enrolled 91 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT03981796 2025-09-03

RUBY

Phase 3 Active not recruiting

785 enrolled 4 FDA

Neoplasms, Recurrence

NCT03329001 2024-07-25

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

Phase 1 Completed

236 enrolled 49 charts

Neoplasms

NCT03308942 2023-10-16

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Phase 2 Completed

53 enrolled 35 charts

Neoplasms

NCT02657889 2022-12-01

TOPACIO

Phase 1/2 Completed

122 enrolled 29 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03221400 2022-02-17

PEN-866 in Patients With Advanced Solid Malignancies

Phase 1/2 Unknown

GastrointestinalThoracic

Anus Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT03359850 2021-05-28

Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients

Phase 1 Completed

17 enrolled 35 charts

Neoplasms, Ovarian Neoplasms

NCT02476552 2020-01-13

Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer

Phase 1 Completed

Neoplasms

NCT01110603 2016-05-05

A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

Phase 1 Terminated

Neoplasms

NCT00749502 2013-07-25

A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)

Phase 1 Completed

GenitourinaryGynecologicLymphoidOther hematologic neoplasm

Adnexal Diseases, Endocrine System Diseases, Endocrine Gland Neoplasms, Genital Diseases, Female, Genital Diseases, Male, Genital Neoplasms, Female, Genital Neoplasms, Male, Gonadal Disorders, Neoplasms, Ovarian Diseases, Ovarian Neoplasms, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell

NCT01226901 2012-06-28

A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)

Phase 1 Terminated

Neoplasms